Ï㽶ÊÓƵ

Casey J. Mehrhoff
No Rating Available
(Learn About Our Rating System)

Casey J. Mehrhoff, DO, MS

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-587-4745

Ï㽶ÊÓƵ of Utah Hospital

Salt Lake City
801-662-4700

  • Dr. Casey Mehrhoff received her Master of Science in Biomedical Sciences and medical degree from Kansas City Ï㽶ÊÓƵ of Medicine, completed her Pediatric Residency at Loyola Ï㽶ÊÓƵ Medical Center in Chicago, and her Pediatric Hematology/Oncology Fellowship at Ann & Robert H. Lurie Children's Hospital of Chicago. She is currently an Assistant Professor of Pediatrics at the Ï㽶ÊÓƵ of Utah within the Division of Pediatric Hematology/Oncology at Primary Children's Hospital. Her clinical focus is on pediatric patients with solid tumor malignancies, with a specific focus on patients diagnosed with rare tumors and patients with cancer predisposition syndromes. She is the co-director and co-founder of the Pediatric Multidisciplinary Thyroid Team and is the co-director and founder of the Pediatric Multidisciplinary Melanoma program and is involved with these specialties on a national level. She is a provider in the high risk genetics cancer predisposition clinic at Huntsman Cancer Institute where she provides care and cancer screening for patients with certain cancer predisposition syndromes, such as Li Fraumeni Syndrome, DICER1, and Familial Adenomatous Polyposis, to name a few. Her research interest is in translational research and clinical trials.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. Casey Mehrhoff received her Master of Science in Biomedical Sciences and medical degree from Kansas City Ï㽶ÊÓƵ of Medicine, completed her Pediatric Residency at Loyola Ï㽶ÊÓƵ Medical Center in Chicago, and her Pediatric Hematology/Oncology Fellowship at Ann & Robert H. Lurie Children's Hospital of Chicago. She is currently an Assistant Professor of Pediatrics at the Ï㽶ÊÓƵ of Utah within the Division of Pediatric Hematology/Oncology at Primary Children's Hospital. Her clinical focus is on pediatric patients with solid tumor malignancies, with a specific focus on patients diagnosed with rare tumors and patients with cancer predisposition syndromes. She is the co-director and co-founder of the Pediatric Multidisciplinary Thyroid Team and is the co-director and founder of the Pediatric Multidisciplinary Melanoma program and is involved with these specialties on a national level. She is a provider in the high risk genetics cancer predisposition clinic at Huntsman Cancer Institute where she provides care and cancer screening for patients with certain cancer predisposition syndromes, such as Li Fraumeni Syndrome, DICER1, and Familial Adenomatous Polyposis, to name a few. Her research interest is in translational research and clinical trials.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Fellowship Osteosarcoma - Ann & Robert H. Lurie Children’s Hospital Clinical Research Fellow
    Fellowship Pediatric Hematology/Oncology - Northwestern Ï㽶ÊÓƵ Feinberg School of Medicine Fellow
    Residency Pediatrics - Loyola Ï㽶ÊÓƵ Medical Center Resident
    Professional Medical Osteopathic Medicine - Kansas City Ï㽶ÊÓƵ College of Osteopathic Medicine D.O.
    Graduate Training Biomedical Sciences - Kansas City Ï㽶ÊÓƵ M.S.
    Undergraduate Majors: Chemistry and Biology; Minors: Global Awareness and Business Development - Drury Ï㽶ÊÓƵ B.A.

    Selected Publications

    Journal Article

    1. Ramesh S, Dyer E, Pomaville M, Doytcheva K, Dolezal J, Kochanny S, Terhaar R, Mehrhoff CJ, Patel K, Brewer J, Kusswurm B, Naranjo A, Shimada H, Cipriani NA, Husain AN, Pytel P, Sokol EA, Cohn SL, George RE, Pearson AT, Applebaum MA (2024). Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. NPJ Precis Oncol, 8(1), 255. ()
    2. Sargen MR, Barnhill RL, Elder DE, Swetter SM, Prieto VG, Ko JS, Bahrami A, Gerami P, Karunamurthy A, Pappo AS, Schuchter LM, LeBoit PE, Yeh I, Kirkwood JM, Jen M, Dunkel IJ, Durham MM, Christison-Lagay ER, Austin MT, Aldrink JH, Mehrhoff C, Hawryluk EB, Chu EY, Busam KJ, Sondak V, Messina J, Puig S, Colebatch AJ, Coughlin CC, Berrebi KG, Laetsch TW, Mitchell SG, Seynnaeve B (2024). Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. J Clin Oncol, JCO2401154. ()
    3. Applebaum M, Ramesh S, Dyer E, Pomaville M, Doytcheva K, Dolezal J, Kochanny S, Terhaar R, Mehrhoff C, Patel K, Brewer J, Kusswurm B, Naranjo A, Shimada H, Sokol E, Cohn S, George R, Pearson A (2024). Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. Res Sq. ()
    4. Long CM, Mehrhoff C, Abdel-Latief E, Rech M, Laubham M (2018). Factors Influencing Pediatric Emergency Department Visits for Low-Acuity Conditions. Pediatr Emerg Care, 37(5), 265-268. ()
    5. Roy LN, Roy RN, Allen KA, Mehrhoff CJ, Henson IB, Stegner JM (2012). Buffer standards for the physiological pH of the zwitterionic compound of 3-(N-morpholino)propanesulfonic acid (MOPS) from T = (278.15 to 328.15) K. J Chem Thermodyn, 47, 21-27. ()
    6. Roy LN, Roy RN, Allen KA, Mehrhoff CJ, Henson IB, Stegner JM, Downs ZM (2012). Buffer Standards for the Physiological pH of N-(2-Hydroxyethyl)piperazine-N’-4-butanesulfonic Acid (HEPBS) from 5 to 55oC. Open Electrochemistry Journal, 4(1), 20-7.
    7. Roy RN, Roy LN, Allen KA, Mehrhoff CJ, Henson IB, Stegner JM, Jenkins AL, Shah AA, Rhocchio SD (2012). Buffers for the Physiological pH Range: Studies of 4-(N-Morpholino) butanesulfonic Acid (MOBS) from 5 to 55oC. J Solution Chem, 41(6), 1044-53.
    8. Roy LN, Roy RN, Wolen JT, Bwashi A, Stegner JM, Down ZM, Mehrhoff CJ, Bodendorfer BM, Allen KA, Harmon MA, Henson IB (2009). 3-[4-(2 Hydroxyethyl)-1-piperazinyl]propanesulfonic Acid (HEPPS) and the pH of its Buffer Solutions from (278.15 to 328.15)K. J Chem Eng Data, 55(3), 1327-32.

    Review

    1. Mehrhoff CJ, Vagher J, Florou V, Maese LD (2024). Genetic Predisposition to Sarcoma: What Should Clinicians Know? [Review]. Curr Treat Options Oncol, 25(6), 769-783. ()

    Case Report

    1. Mehrhoff CJ, Hemenway CS, Suh E (2019). Emergence of a Ph-negative Clone in a Child With Ph+ ALL. J Pediatr Hematol Oncol, 42(6), e466-e468. ()